Literature DB >> 30082847

Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis.

Shunsuke Misono1, Naohiko Seki2, Keiko Mizuno1, Yasutaka Yamada3, Akifumi Uchida1, Takayuki Arai3, Tomohiro Kumamoto1, Hiroki Sanada1, Takayuki Suetsugu1, Hiromasa Inoue1.   

Abstract

Our original microRNA (miRNA) expression signatures (based on RNA sequencing) revealed that both strands of the miR-145 duplex (miR-145-5p, the guide strand, and miR-145-3p, the passenger strand) were downregulated in several types of cancer tissues. Involvement of passenger strands of miRNAs in cancer pathogenesis is a new concept in miRNA biogenesis. In our continuing analysis of lung adenocarcinoma (LUAD) pathogenesis, we aimed here to identify important oncogenes that were controlled by miR-145-5p and miR-145-3p. Downregulation of miR-145-5p and miR-145-3p was confirmed in LUAD clinical specimens. Functional assays showed that miR-145-3p significantly blocked the malignant abilities in LUAD cells, e.g., cancer cell proliferation, migration and invasion. Thus, the data showed that expression of the passenger strand of the miR-145-duplex acted as an anti-tumor miRNA. In LUAD cells, we identified four possible target genes (LMNB2, NLN, SIX4, and DDC) that might be regulated by both strands of miR-145. Among the possible targets, high expression of LMNB2 predicted a significantly poorer prognosis of LUAD patients (disease-free survival, p = 0.0353 and overall survival, p = 0.0017). Overexpression of LMNB2 was detected in LUAD clinical specimens and its aberrant expression promoted malignant transformation of LUAD cells. Genes regulated by anti-tumor miR-145-5p and miR-145-3p are closely involved in the molecular pathogenesis of LUAD. We suggest that they are promising prognostic markers for this disease. Our approach, based on the roles of anti-tumor miRNAs, will contribute to improved understanding of the molecular pathogenesis of LUAD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30082847     DOI: 10.1038/s10038-018-0497-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  47 in total

Review 1.  Pathology of lung cancer.

Authors:  William D Travis
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

2.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

3.  Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group.

Authors:  T Arai; T Kuroishi; Y Saito; Y Kurita; T Naruke; M Kaneko
Journal:  Jpn J Clin Oncol       Date:  1994-08       Impact factor: 3.019

Review 4.  Nuclear lamin functions and disease.

Authors:  Veronika Butin-Israeli; Stephen A Adam; Anne E Goldman; Robert D Goldman
Journal:  Trends Genet       Date:  2012-07-12       Impact factor: 11.639

Review 5.  Nuclear lamins: key regulators of nuclear structure and activities.

Authors:  Miron Prokocimer; Maya Davidovich; Malka Nissim-Rafinia; Naama Wiesel-Motiuk; Daniel Z Bar; Rachel Barkan; Eran Meshorer; Yosef Gruenbaum
Journal:  J Cell Mol Med       Date:  2009-02-04       Impact factor: 5.310

Review 6.  Epigenetics and MicroRNAs in Cancer.

Authors:  Alice Ramassone; Sara Pagotto; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-02-03       Impact factor: 5.923

7.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

8.  Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.

Authors:  Keiko Mizuno; Naohiko Seki; Hiroko Mataki; Ryosuke Matsushita; Kazuto Kamikawaji; Tomohiro Kumamoto; Koichi Takagi; Yusuke Goto; Rika Nishikawa; Mayuko Kato; Hideki Enokida; Masayuki Nakagawa; Hiromasa Inoue
Journal:  Int J Oncol       Date:  2015-12-14       Impact factor: 5.650

9.  The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Authors:  Keiichi Yonemori; Naohiko Seki; Tetsuya Idichi; Hiroshi Kurahara; Yusaku Osako; Keiichi Koshizuka; Takayuki Arai; Atsushi Okato; Yoshiaki Kita; Takaaki Arigami; Yuko Mataki; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  Oncotarget       Date:  2017-07-26

10.  Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.

Authors:  Takayuki Arai; Atsushi Okato; Yasutaka Yamada; Sho Sugawara; Akira Kurozumi; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  Cancer Med       Date:  2018-04-02       Impact factor: 4.452

View more
  18 in total

1.  MiR-145 Regulates the Chemoresistance of Hepatic Carcinoma Cells Against 5-Fluorouracil by Targeting Toll-Like Receptor 4.

Authors:  Rui-Peng Zheng; Dong-Kai Ma; Zhuo Li; Hai-Feng Zhang
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

2.  Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes.

Authors:  Yoshiaki Shinden; Tadahiro Hirashima; Nijiro Nohata; Hiroko Toda; Reona Okada; Shunichi Asai; Takako Tanaka; Yuto Hozaka; Takao Ohtsuka; Yuko Kijima; Naohiko Seki
Journal:  J Hum Genet       Date:  2020-11-12       Impact factor: 3.172

3.  RNA sequencing-based microRNA expression signature in esophageal squamous cell carcinoma: oncogenic targets by antitumor miR-143-5p and miR-143-3p regulation.

Authors:  Masumi Wada; Yusuke Goto; Takako Tanaka; Reona Okada; Shogo Moriya; Tetsuya Idichi; Masahiro Noda; Ken Sasaki; Yoshiaki Kita; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe; Naohiko Seki
Journal:  J Hum Genet       Date:  2020-07-04       Impact factor: 3.172

4.  Aspirin ameliorates lung cancer by targeting the miR-98/WNT1 axis.

Authors:  Huizhu Gan; Lin Lin; Nanjun Hu; Yang Yang; Yu Gao; Yu Pei; Kang Chen; Butong Sun
Journal:  Thorac Cancer       Date:  2019-02-12       Impact factor: 3.500

5.  Involvement of Dual Strands of miR-143 (miR-143-5p and miR-143-3p) and Their Target Oncogenes in the Molecular Pathogenesis of Lung Adenocarcinoma.

Authors:  Hiroki Sanada; Naohiko Seki; Keiko Mizuno; Shunsuke Misono; Akifumi Uchida; Yasutaka Yamada; Shogo Moriya; Naoko Kikkawa; Kentaro Machida; Tomohiro Kumamoto; Takayuki Suetsugu; Hiromasa Inoue
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

6.  miR-223-5p targeting ERG inhibits prostate cancer cell proliferation and migration.

Authors:  Yongbao Wei; Junming Peng; Shuyun He; Haijian Huang; Le Lin; Qingguo Zhu; Liefu Ye; Tao Li; Xing Zhang; Yunliang Gao; Xiaochun Zheng
Journal:  J Cancer       Date:  2020-05-18       Impact factor: 4.207

7.  MiR-145-targeted HBXIP modulates human breast cancer cell proliferation.

Authors:  Yang Jiang; Dan Wang; Hui Ren; Ying Shi; Yufei Gao
Journal:  Thorac Cancer       Date:  2018-10-31       Impact factor: 3.500

8.  Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.

Authors:  Akifumi Uchida; Naohiko Seki; Keiko Mizuno; Shunsuke Misono; Yasutaka Yamada; Naoko Kikkawa; Hiroki Sanada; Tomohiro Kumamoto; Takayuki Suetsugu; Hiromasa Inoue
Journal:  Cancer Sci       Date:  2018-12-06       Impact factor: 6.716

9.  Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma.

Authors:  Shunsuke Misono; Naohiko Seki; Keiko Mizuno; Yasutaka Yamada; Akifumi Uchida; Hiroki Sanada; Shogo Moriya; Naoko Kikkawa; Tomohiro Kumamoto; Takayuki Suetsugu; Hiromasa Inoue
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

10.  Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival.

Authors:  Ramkrishna Mitra; Clare M Adams; Wei Jiang; Evan Greenawalt; Christine M Eischen
Journal:  Nat Commun       Date:  2020-02-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.